Xenon Pharmaceuticals Inchares (NASDAQ:XENE) Can’t Be More Risky. Short Interest Increased

June 15, 2018 - By Louis Casey

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Logo

The stock of Xenon Pharmaceuticals Inchares (NASDAQ:XENE) registered an increase of 5.71% in short interest. XENE’s total short interest was 148,000 shares in June as published by FINRA. Its up 5.71% from 140,000 shares, reported previously. With 155,300 shares average volume, it will take short sellers 1 days to cover their XENE’s short positions. The short interest to Xenon Pharmaceuticals Inchares’s float is 1.28%.

The stock increased 3.11% or $0.25 during the last trading session, reaching $8.3. About 69,850 shares traded. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has risen 39.24% since June 15, 2017 and is uptrending. It has outperformed by 26.67% the S&P500.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $117.63 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

More recent Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news were published by: Nasdaq.com which released: “Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference” on May 17, 2018. Also Benzinga.com published the news titled: “42 Biggest Movers From Yesterday” on June 13, 2018. Benzinga.com‘s news article titled: “41 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: